Sydney Lupkin
Sydney Lupkin is an accomplished pharmaceuticals correspondent for NPR. She has previously worked at Kaiser Health News, where she covered drug prices and specialized in data reporting. Her work has won several awards and recognitions. Sydney focuses on ensuring patients have access to needed medicines while also highlighting potential dangers posed by unapproved or tainted drugs. Her reporting covers a wide range of topics related to pharmaceuticals, including drug shortages, pricing, and rare disease drugs. She is dedicated to providing accurate and informative content to her audience.
74%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
87%
Examples:
- Sydney Lupkin's reporting on the FDA's approval of Florida's plan to import cheaper drugs from Canada shows a slight leaning towards ensuring patients have access to needed medicines, while also acknowledging the potential dangers posed by the importation of unapproved medicines.
Conflicts of Interest
95%
Examples:
- In an article about a popular asthma inhaler leaving pharmacy shelves, Sydney Lupkin mentions that some patients who rely on Flovent are being advised to take action to ensure they can get the medication in 2024. This could be seen as promoting fear or uncertainty around the availability of the medication.
Contradictions
95%
Examples:
- In an article about a persistent shortage of growth hormone, Sydney Lupkin mentions that Norditropin, the most commonly prescribed growth hormone, went into shortage in fall 2022 and is still scarce. She also highlights the issues faced by patients with Prader-Willi syndrome due to this shortage.
Deceptions
35%
Examples:
- In an article about Ozempic, Sydney Lupkin mentions that reports to the FDA about possible side effects are rising as more people try it for weight loss. This could be seen as implying a causal relationship between Ozempic use and the reported side effects without providing definitive evidence.
Recent Articles
Norditropin Shortage Causes Frustration for Children with Prader-Willi Syndrome and Their Clinicians
Broke On: Wednesday, 17 April 2024Since fall 2022, a shortage of Norditropin, the most commonly prescribed growth hormone, has caused significant frustration for parents and clinicians. The scarcity has had particularly notable consequences for children with Prader-Willi syndrome, leading to behavioral issues and school absences. Dr. Jennifer Miller at the University of Florida's College of Medicine reports a high volume of calls regarding the shortage from patients across the U.S., while insurance companies' prior authorization requirements add to the problem. Florida Granted First State to Import Prescription Drugs from Canada, Pharmaceutical Companies Fight Back
Broke On: Friday, 05 January 2024Florida becomes the first state to import prescription drugs from Canada, in a bid to reduce costs. However, pharmaceutical companies have already signaled their intention to fight this plan.
